FTSE MIB
33.130,06 -83,23 (-0,25%) Dow Jones
40.736,96 -92,63 (-0,23%) Nasdaq
17.025,88 +141,28 (+0,84%) Nikkei 225
35.619,77 -539,39 (-1,49%) Petrolio
67,39 +1,64 (+2,49%) Bitcoin EUR
51.286,07 -459,91 (-0,89%)
Anavex Life Sciences Corp. (0HFR.L)
| Chiusura precedente | 5,16 |
| Aperto | 5,16 |
| Denaro | 0,00 x N/D |
| Domanda | 0,00 x N/D |
| Min-Max giorno | 4,98 - 5,16 |
| Intervallo di 52 settimane | 4,80 - 10,45 |
| Volume | |
| Media Volume | 7.784 |
| Capitalizzazione | 288,141M |
| Beta (mensile su 5 anni) | 0,62 |
| Rapporto PE (ttm) | N/D |
| EPS (ttm) | -0,58 |
| Prossima data utili | 25 nov 2024 - 29 nov 2024 |
| Rendimento e dividendo (futuro) | N/D (N/D) |
| Data ex dividendo | N/D |
| Stima target 1A | N/D |
GlobeNewswireAnavex’s Phase 2b/3 Trial of Blarcamesine (ANAVEX®2-73) in Patients with Alzheimer’s Disease Shows Robust Clinical Efficacy and Slows Neurodegeneration
Significant Reduction of Amyloid Beta Biomarkers of Alzheimer’s PathologyNEW YORK, Sept. 14, 2023 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders announced today that a follow-on analysis of the landmark Phase 2b/3 study to treat early Alzheimer’s disease with the investigational drug blarcamesine (ANA
- GlobeNewswire
Anavex Announces Appointment of Dr. Marwan N Sabbagh, MD as Chairman of the Scientific Advisory Board
NEW YORK, Sept. 12, 2023 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including Alzheimer’s disease, Parkinson’s disease, Rett syndrome and other central nervous system (CNS) diseases, today announced the appointment of Prof. Dr. Marwan N Sabbagh, MD, as Chairman of the Scientific Advisory Board. Pr
